NCT00027742View on ClinicalTrials.gov

Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma

PHASE2CompletedINTERVENTIONAL
Timeline

Start Date

May 31, 2001

Primary Completion Date

June 30, 2005

Study Completion Date

June 30, 2005

Conditions
Intraocular MelanomaMelanoma (Skin)
Interventions
BIOLOGICAL

pegylated interferon alfa

DRUG

temozolomide

Trial Locations (1)

10021

Memorial Sloan-Kettering Cancer Center, New York

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT00027742 - Temozolomide and Interferon Alfa in Treating Patients With Stage III or Stage IV Melanoma | Biotech Hunter | Biotech Hunter